Synthesis of Indoles via 6π-Electrocyclic Ring Closures of Trienecarbamates
摘要:
A new method for the preparation of indoles from readily available alpha-haloenones and alpha-(trialkylstannyl)enecarbamates is described. Following a Stille coupling, trienecarbamate 2 is electronically activated to undergo a facile 6pi-electrocyclic ring closure and subsequent oxidation to afford protected aniline 4. Upon deprotection and reductive amination, acid 5 underwent clean cyclization to N-acetylindole 6 (Ac2O, NEt3, 130 degrees C). This method has been used to construct a variety of substituted indoles that are not easily prepared by conventional indole annelation methods.
Synthesis of Indoles via 6π-Electrocyclic Ring Closures of Trienecarbamates
摘要:
A new method for the preparation of indoles from readily available alpha-haloenones and alpha-(trialkylstannyl)enecarbamates is described. Following a Stille coupling, trienecarbamate 2 is electronically activated to undergo a facile 6pi-electrocyclic ring closure and subsequent oxidation to afford protected aniline 4. Upon deprotection and reductive amination, acid 5 underwent clean cyclization to N-acetylindole 6 (Ac2O, NEt3, 130 degrees C). This method has been used to construct a variety of substituted indoles that are not easily prepared by conventional indole annelation methods.
[EN] QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] DERIVES DE QUINOLEINE UTILISES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE
申请人:GLAXO GROUP LTD
公开号:WO2004103998A1
公开(公告)日:2004-12-02
There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
Quinoline derivatives as phosphodiesterase inhibitors
申请人:Baldwin Robert Ian
公开号:US20070142373A1
公开(公告)日:2007-06-21
There are provided according to the invention novel compounds of formula (I)
or pharmaceutically acceptable salts thereof, wherein R
1
, R
2,
R
19,
R
20,
and R
34
are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
Quinoline derivatives as phosphodiesterase inhibitors
申请人:GLAXO GROUP LIMITED
公开号:EP1944305A1
公开(公告)日:2008-07-16
There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.